Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2312499121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Roland Windisch und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, G…. Hauptthemen laut MEDLINE: Phagocytes, Cell Differentiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Volkswagen Foundation (VolkswagenStiftung), Friedrich-Baur-Stiftung (Friedrich Baur Stiftung), Metiphys program.
Abstract (Originalsprache)
Ex vivo expansion of human CD34+ hematopoietic stem and progenitor cells remains a challenge due to rapid differentiation after detachment from the bone marrow niche. In this study, we assessed the capacity of an inducible fusion protein to enable sustained ex vivo proliferation of hematopoietic precursors and their capacity to differentiate into functional phagocytes. We fused the coding sequences of an FK506-Binding Protein 12 (FKBP12)-derived destabilization domain (DD) to the myeloid/lymphoid lineage leukemia/eleven nineteen leukemia (MLL-ENL) fusion gene to generate the fusion protein DD-MLL-ENL and retrovirally expressed the protein switch in human CD34+ progenitors. Using Shield1, a chemical inhibitor of DD fusion protein degradation, we established large-scale and long-term expansion of late monocytic precursors. Upon Shield1 removal, the cells lost self-renewal capacity and spontaneously differentiated, even after 2.5 y of continuous ex vivo expansion. In the absence of Shield1, stimulation with IFN-γ, LPS, and GM-CSF triggered terminal differentiation. Gene expression analysis of the obtained phagocytes revealed marked similarity with naïve monocytes. In functional assays, the novel phagocytes migrated toward CCL2, attached to VCAM-1 under shear stress, produced reactive oxygen species, and engulfed bacterial particles, cellular particles, and apoptotic cells. Finally, we demonstrated Fcγ receptor recognition and phagocytosis of opsonized lymphoma cells in an antibody-dependent manner. Overall, we have established an engineered protein that, as a single factor, is useful for large-scale ex vivo production of human phagocytes. Such adjustable proteins have the potential to be applied as molecular tools to produce functional immune cells for experimental cell-based approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
- Vascular Biology, Institute for Stroke and Dementia Research, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
- Department of Anesthesiology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
- Biomedical Center, Department of Physiological Genomics, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
- Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
- German Cancer Consortium, Partner site Munich, Munich 81377, Germany.
ORCID-Profile: Roland Windisch, Linping Chen-Wichmann, Sebastian Vosberg, Christian Kellner, Alexander Fischer, Claudia Gebhard, Fabian Beier, Carolin Dorothea Strobl, Oliver Weigert, Michael Schündeln, Michael Rehli, Jürgen Bernhagen, Hannes Klump, Christian Brendel, Daniela S Krause, Philipp A Greif
Förderung
- Volkswagen Foundation (VolkswagenStiftung)
- Friedrich-Baur-Stiftung (Friedrich Baur Stiftung)
- Metiphys program
- José Carreras Leukämie-Stiftung (DJCLS)
- Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
- Deutsche Forschungsgemeinschaft (DFG)
- DFG under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology
- Munich Clinician Scientist Program
Zitieren
APA
Windisch, R., Soliman, S., Hoffmann, A., Chen-Wichmann, L., Danese, A., Vosberg, S., Bravo, J., Lutz, S., Kellner, C., Fischer, A., Gebhard, C., Redondo Monte, E., Hartmann, L., Schneider, S., Beier, F., Strobl, C. D., Weigert, O., Peipp, M., Schündeln, M., …, & Wichmann, C. (2024). Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2312499121
Vancouver
Windisch R, Soliman S, Hoffmann A, Chen-Wichmann L, Danese A, Vosberg S, et al. Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2312499121
BibTeX
@article{Windisch2024,
author = {Windisch, Roland and Soliman, Sarah and Hoffmann, Adrian and Chen-Wichmann, Linping and Danese, Anna and Vosberg, Sebastian and Bravo, Jimena and Lutz, Sebastian and Kellner, Christian and Fischer, Alexander and Gebhard, Claudia and Redondo Monte, Enric and Hartmann, Luise and Schneider, Stephanie and Beier, Fabian and Strobl, Carolin Dorothea and Weigert, Oliver and Peipp, Matthias and Schündeln, Michael and Stricker, Stefan H and Rehli, Michael and Bernhagen, Jürgen and Humpe, Andreas and Klump, Hannes and Brendel, Christian and Krause, Daniela S and Greif, Philipp A and Wichmann, Christian},
title = {Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2312499121}
}
EUVIMED